APOL1 Renal-Risk Variants Do Not Associate With Incident Cardiovascular Disease or Mortality in the Systolic Blood Pressure Intervention Trial
Relationships between apolipoprotein L1 gene (APOL1) renal-risk variants (RRVs) and cardiovascular disease (CVD) remain controversial. To clarify associations between APOL1 and CVD, a total of 2568 African American Systolic Blood Pressure Intervention Trial (SPRINT) participants were assessed for th...
Main Authors: | Barry I. Freedman, Michael V. Rocco, Jeffrey T. Bates, Michel Chonchol, Amret T. Hawfield, James P. Lash, Vasilios Papademetriou, John R. Sedor, Karen Servilla, Paul L. Kimmel, Barry M. Wall, Nicholas M. Pajewski |
---|---|
Format: | Article |
Language: | English |
Published: |
Elsevier
2017-07-01
|
Series: | Kidney International Reports |
Subjects: | |
Online Access: | http://www.sciencedirect.com/science/article/pii/S2468024917300621 |
Similar Items
-
APOL1 Risk Variants and Subclinical Cardiovascular Disease in Incident Hemodialysis Patients
by: Teresa K. Chen, et al.
Published: (2021-02-01) -
APOL1 Risk Variants Independently Associated With Early Cardiovascular Disease Death
by: Michael D. Hughson, et al.
Published: (2018-01-01) -
HIV Viremia Is Associated With APOL1 Variants and Reduced JC-Viruria
by: Etty Kruzel-Davila, et al.
Published: (2021-08-01) -
Recessive, gain-of-function toxicity in an APOL1 BAC transgenic mouse model mirrors human APOL1 kidney disease
by: Gizelle M. McCarthy, et al.
Published: (2021-08-01) -
Impact of APOL1 Genetic Variants on HIV-1 Infection and Disease Progression
by: Ping An, et al.
Published: (2019-01-01)